|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CTU2 |
Gene summary for CTU2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CTU2 | Gene ID | 348180 |
| Gene name | cytosolic thiouridylase subunit 2 | |
| Gene Alias | C16orf84 | |
| Cytomap | 16q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0002097 | UniProtAcc | Q2VPK5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 348180 | CTU2 | LZE7T | Human | Esophagus | ESCC | 2.44e-06 | 2.21e-01 | 0.0667 |
| 348180 | CTU2 | LZE20T | Human | Esophagus | ESCC | 9.14e-04 | 1.41e-01 | 0.0662 |
| 348180 | CTU2 | LZE24T | Human | Esophagus | ESCC | 1.67e-09 | 2.01e-01 | 0.0596 |
| 348180 | CTU2 | P2T-E | Human | Esophagus | ESCC | 3.88e-10 | 2.03e-01 | 0.1177 |
| 348180 | CTU2 | P4T-E | Human | Esophagus | ESCC | 9.80e-06 | 1.90e-01 | 0.1323 |
| 348180 | CTU2 | P5T-E | Human | Esophagus | ESCC | 1.69e-10 | 1.61e-01 | 0.1327 |
| 348180 | CTU2 | P8T-E | Human | Esophagus | ESCC | 6.52e-16 | 2.20e-01 | 0.0889 |
| 348180 | CTU2 | P9T-E | Human | Esophagus | ESCC | 6.71e-05 | 1.37e-01 | 0.1131 |
| 348180 | CTU2 | P10T-E | Human | Esophagus | ESCC | 3.68e-12 | 2.43e-01 | 0.116 |
| 348180 | CTU2 | P11T-E | Human | Esophagus | ESCC | 2.76e-05 | 2.49e-01 | 0.1426 |
| 348180 | CTU2 | P12T-E | Human | Esophagus | ESCC | 2.01e-25 | 2.65e-01 | 0.1122 |
| 348180 | CTU2 | P15T-E | Human | Esophagus | ESCC | 2.14e-11 | 2.49e-01 | 0.1149 |
| 348180 | CTU2 | P16T-E | Human | Esophagus | ESCC | 1.05e-08 | 1.63e-01 | 0.1153 |
| 348180 | CTU2 | P17T-E | Human | Esophagus | ESCC | 5.21e-08 | 4.11e-01 | 0.1278 |
| 348180 | CTU2 | P19T-E | Human | Esophagus | ESCC | 3.08e-03 | 3.30e-01 | 0.1662 |
| 348180 | CTU2 | P20T-E | Human | Esophagus | ESCC | 4.95e-12 | 2.28e-01 | 0.1124 |
| 348180 | CTU2 | P21T-E | Human | Esophagus | ESCC | 1.89e-22 | 3.00e-01 | 0.1617 |
| 348180 | CTU2 | P22T-E | Human | Esophagus | ESCC | 1.26e-16 | 1.36e-01 | 0.1236 |
| 348180 | CTU2 | P23T-E | Human | Esophagus | ESCC | 3.36e-20 | 5.09e-01 | 0.108 |
| 348180 | CTU2 | P24T-E | Human | Esophagus | ESCC | 4.98e-14 | 1.62e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:00080333 | Esophagus | ESCC | tRNA processing | 92/8552 | 127/18723 | 7.83e-10 | 1.93e-08 | 92 |
| GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
| GO:00094512 | Esophagus | ESCC | RNA modification | 114/8552 | 167/18723 | 2.76e-09 | 6.04e-08 | 114 |
| GO:00064002 | Esophagus | ESCC | tRNA modification | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
| GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:00080332 | Oral cavity | OSCC | tRNA processing | 78/7305 | 127/18723 | 2.56e-07 | 4.00e-06 | 78 |
| GO:00063991 | Oral cavity | OSCC | tRNA metabolic process | 101/7305 | 179/18723 | 1.65e-06 | 2.15e-05 | 101 |
| GO:00094511 | Oral cavity | OSCC | RNA modification | 95/7305 | 167/18723 | 2.05e-06 | 2.62e-05 | 95 |
| GO:00064001 | Oral cavity | OSCC | tRNA modification | 53/7305 | 90/18723 | 1.04e-04 | 7.70e-04 | 53 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CTU2 | SNV | Missense_Mutation | rs370063135 | c.1126N>T | p.Arg376Trp | p.R376W | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CTU2 | SNV | Missense_Mutation | novel | c.1627N>T | p.Asp543Tyr | p.D543Y | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0C1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| CTU2 | SNV | Missense_Mutation | c.143N>T | p.Arg48Met | p.R48M | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-D8-A1X9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | ||
| CTU2 | insertion | Frame_Shift_Ins | novel | c.133_134insGGGCGAGGACTACGGGGAGCCGGCGCCTGAGGAGCCGCCC | p.Ala45GlyfsTer63 | p.A45Gfs*63 | protein_coding | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |||
| CTU2 | SNV | Missense_Mutation | c.724N>A | p.Glu242Lys | p.E242K | protein_coding | tolerated(0.6) | benign(0.003) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| CTU2 | SNV | Missense_Mutation | novel | c.437C>A | p.Ala146Asp | p.A146D | protein_coding | tolerated_low_confidence(0.13) | benign(0.017) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CTU2 | SNV | Missense_Mutation | novel | c.1072C>A | p.Leu358Met | p.L358M | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CTU2 | SNV | Missense_Mutation | novel | c.1286N>A | p.Pro429His | p.P429H | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CTU2 | SNV | Missense_Mutation | c.572G>A | p.Gly191Asp | p.G191D | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CTU2 | SNV | Missense_Mutation | c.90N>T | p.Lys30Asn | p.K30N | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |